# Modus Therapeutics Holding > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/modustherapeuticsholding). ## Overview Modus Therapeutics Holding is a Swedish biotechnology group focused on developing sevuparin, a patented low-anticoagulant heparinoid drug candidate. The company operates through its wholly owned subsidiary Modus Therapeutics AB and is centered on clinical development for severe diseases with high unmet medical need. ## Products & services • Sevuparin drug development • Phase IIa CKD-anemia clinical program • Severe malaria collaboration program • Preclinical and early clinical research • Partnering and collaboration model - **Sevuparin development** (100%) — Clinical and preclinical development of the sevuparin drug candidate across target indications. - **Collaborative research programs** (0%) — Externally partnered studies and scientific collaborations supporting indication expansion. - Sevuparin drug candidate development - Phase IIa CKD-anemia clinical studies - Severe malaria collaboration research - Preclinical and early clinical evaluation - Partnership-based development model ## Customers Modus does not sell a commercialized drug to end customers; its value creation is directed toward future partners, licensors, and development collaborators. The main counterparties are research institutions, clinical study sites, and potential pharmaceutical partners that can advance or commercialize sevuparin in specific indications. - **Pharmaceutical partnering companies** (primary) — Potential partners that may license, co-develop, or commercialize sevuparin after clinical value is established. - **Clinical research sites** (primary) — Hospitals and investigators that enroll patients and generate trial data for CKD-anemia and other programs. - **Academic and scientific collaborators** (secondary) — Universities and research groups that support mechanism, indication, and translational studies. - **Non-dilutive funding partners** (secondary) — Organizations that may fund selected programs such as severe malaria research. - Pharmaceutical partners seeking late-stage assets - Clinical investigators and study sites running trials - Academic collaborators supporting disease research - Potential licensees in CKD and infectious disease - Funding partners for non-dilutive research support ## Geography Modus is headquartered in Stockholm, Sweden, and its operating structure is centered in Sweden through the parent company and wholly owned subsidiary. Its clinical and collaboration footprint extends into Europe, including study sites in Italy and partnerships with international research institutions for selected programs. - **Sweden** (60%) — Corporate headquarters, management, and core operations - **Europe** (40%) — Clinical sites and research collaborations, including Italy and UK-linked partners - Head office in Stockholm, Sweden - Operations conducted through Swedish parent and subsidiary - Clinical study sites in Verona and Pavia, Italy - European partnering activity through BioEurope events - International research collaboration for severe malaria ## Strategy Modus is focused on building clinical evidence for sevuparin in CKD with anemia, then using that data to support partnering with established commercial players. A second strategic pillar is selective expansion into other severe diseases, especially where external funding or collaboration can reduce development burden. - **Advance CKD-anemia clinical development** (short-term) — This is the core value driver for sevuparin and the main basis for future partnering. - **Create partnering optionality** (medium-term) — The company aims to realize value through collaborations with players that have commercial reach. - **Pursue selective additional indications** (medium-term) — Broader indication work can increase the asset's value while limiting capital intensity through external support. - Advance sevuparin through defined clinical studies - Build value through robust human data - Pursue partnerships with commercial-stage pharma - Use external funding for selected non-core programs - Expand only where biology and funding support it ## Risks The business is exposed to clinical development risk because sevuparin remains dependent on trial outcomes, patient recruitment, and regulatory progress. It also faces financing risk typical of development-stage biotech companies, since continued operations depend on access to capital and the ability to fund long-duration research programs. - **Drug development failure** [critical] — Sevuparin's value depends on clinical efficacy, safety, and regulatory acceptance. - **Financing risk** [high] — The company is research-intensive and relies on external capital to fund operations. - **Trial execution risk** [high] — Recruitment, site performance, and data generation affect timelines and study quality. - **Capital market and macro risk** [medium] — Interest rates, inflation, and geopolitical uncertainty can weaken financing conditions. - Clinical trial failure could reduce or eliminate asset value - Patient recruitment delays can slow development timelines - Future financing may be unavailable or highly dilutive - Partnering success depends on positive clinical data - Macro and geopolitical conditions can affect capital markets ## Accounting Modus is a development-stage biotech with limited revenue, so reported results are driven mainly by operating expenses, related-party invoicing, and financing transactions. Key accounting judgments include whether development costs qualify for capitalization, how equity issuances and warrants are recorded, and how going-concern assumptions are assessed in light of funding needs. - **Development expense capitalization** — Higher current-period expenses and no intangible asset build-up - **Related-party revenue** — Revenue is internal to the group structure and not external sales - **Equity and warrant accounting** — Dilution, cash proceeds, and potential future equity issuance - **Going-concern and financing assumptions** — Material uncertainty disclosure and valuation sensitivity - Development costs are generally expensed unless capitalization criteria are met - Related-party invoicing to the subsidiary drives parent-company turnover - Equity issues and warrants affect share capital and dilution - Going-concern assessment depends on future financing access - Lease accounting is limited to operating leases --- *Last updated: 2026-08-11T04:04:54.641574+00:00*